Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect
- 30 June 2003
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 10 (7) , 540-548
- https://doi.org/10.1038/sj.cgt.7700597
Abstract
TRAIL is a cytokine with a unique ability to induce apoptosis selectively in many transformed cell lines. The instability of TRAIL and the resistance of some cancer cells to TRAIL present the main obstacles for clinical experimentation. We generated an adenovirus expressing full-length TRAIL and tested its efficacy in several cancer cell lines. Ad-TRAIL-infected cancer cells localized full-length TRAIL protein to the cytoplasm and released same-sized TRAIL in the media. Ad-TRAIL was found to induce apoptotic cell death in several cancer cell lines resistant to soluble TRAIL (A549, SKOV3, HT-29 and LNCap) and in TRAIL-sensitive cell lines. Ad-TRAIL, but not soluble TRAIL, induced apoptotic cell death in TRAIL-resistant cell lines, manifested by an increased sub-G1 proportion, caspase-3 activation and PARP cleavage. Ad-TRAIL also induced a media-transferable bystander effect, but only in soluble TRAIL-sensitive cell lines. In conclusion, two novel characteristics of ad-TRAIL were found during this study. First, that ad-TRAIL can induce apoptotic cell death in several cancer cell lines resistant to sTRAIL. Second, that ad-TRAIL induces a media-transferable bystander effect, which is expected to increase its therapeutic value by allowing TRAIL to overcome the locally acting nature and low transduction rate commonly encountered in clinical situation.Keywords
This publication has 16 references indexed in Scilit:
- Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cellsOncogene, 2002
- Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell lineGene Therapy, 2002
- Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAILCancer Gene Therapy, 2002
- Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer CellsJournal of Biological Chemistry, 2001
- NF-κB Activation Is Related to the Resistance of Lung Cancer Cells to TNF-α-Induced ApoptosisBiochemical and Biophysical Research Communications, 2000
- Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapyProceedings of the National Academy of Sciences, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- How TRAIL Kills Cancer Cells, But Not Normal CellsScience, 1997
- An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAILScience, 1997
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995